ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Medicines Company (MDCO) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Medicines Company (MDCO)

Rating: Hold Volatility: Conservative
Total Grade: C Industry: Pharmaceuticals
Competitors: MRK,SUPN,HSKA,AMPH

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: C down upgrade
Last Week: D same no change
Two Weeks Ago: D up downgrade
service keys

Medicines Company© quotemedia

Company Profile

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has a collaboration agreement with Alnylam Pharmaceuticals, Inc.; and strategic partnership with SymBio Pharmaceuticals Ltd. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.